Evolent Health, Inc.
EVHNYSEHealthcare● Active
$4.80
+$0.58(+13.63%)
Market Cap$539346716
P/E Ratio—
52W High$12.065
52W Low$2.095
Evolent Health, Inc. (EVH) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
EVH · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
-$0.02
Est. -$0.05 · +60.0%
Revenue
$0.50B
Est. $0.53B · -7.1%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▲ Beat EPS▼ Miss Revenue✓ 2-Quarter EPS Beat Streak
EVH reports quarterly as a NYSE-listed Medical - Healthcare Information Services company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.36
Rev. $5.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.36
Rev. Est.$5.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | -$0.03 | — | — | — | $0.60B | — |
| ▲ Q2 FY2026 | May 7, 2026 | -$0.05 | -$0.02 | +60.0% | $0.50B | $0.53B | -7.1% |
| ▲ Q1 FY2026 | Feb 24, 2026 | $0.06 | $0.08 | +33.3% | $0.47B | $0.47B | +0.0% |
| ▼ Q4 FY2025 | Nov 6, 2025 | $0.10 | $0.05 | -50.0% | $0.48B | $0.47B | +2.4% |
| ▼ Q3 FY2025 | Aug 7, 2025 | $0.09 | -$0.10 | -211.1% | $0.44B | $0.53B | -16.5% |
| ▼ Q2 FY2025 | May 8, 2025 | $0.09 | $0.06 | -33.3% | $0.48B | $0.46B | +5.1% |
| ▼ Q1 FY2025 | Feb 20, 2025 | $0.38 | -$0.02 | -105.3% | $0.65B | $0.65B | -0.7% |
| ▼ Q4 FY2024 | Nov 7, 2024 | $0.30 | $0.04 | -86.7% | $0.62B | $0.65B | -4.7% |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
-$0.03
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Beat
EPS Actual
-$0.02
EPS Est.
-$0.05
EPS Surpr.
+60.0%
Revenue
$0.50B
Q1 FY2026
Feb 24, 2026Beat
EPS Actual
$0.08
EPS Est.
$0.06
EPS Surpr.
+33.3%
Revenue
$0.47B
Q4 FY2025
Nov 6, 2025Miss
EPS Actual
$0.05
EPS Est.
$0.10
EPS Surpr.
-50.0%
Revenue
$0.48B
Q3 FY2025
Aug 7, 2025Miss
EPS Actual
-$0.10
EPS Est.
$0.09
EPS Surpr.
-211.1%
Revenue
$0.44B
Q2 FY2025
May 8, 2025Miss
EPS Actual
$0.06
EPS Est.
$0.09
EPS Surpr.
-33.3%
Revenue
$0.48B
Q1 FY2025
Feb 20, 2025Miss
EPS Actual
-$0.02
EPS Est.
$0.38
EPS Surpr.
-105.3%
Revenue
$0.65B
Q4 FY2024
Nov 7, 2024Miss
EPS Actual
$0.04
EPS Est.
$0.30
EPS Surpr.
-86.7%
Revenue
$0.62B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2029 | $0.20 | $0.22 | $0.24 | 2 |
| Q3 FY2029 | $0.22 | $0.24 | $0.26 | 2 |
| Q2 FY2029 | $0.20 | $0.22 | $0.24 | 2 |
| Q1 FY2029 | $0.14 | $0.15 | $0.16 | 4 |
| Q4 FY2028 | $0.10 | $0.11 | $0.12 | 5 |
| Q3 FY2028 | $0.09 | $0.10 | $0.11 | 5 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2029 | $0.9B | $0.9B | $1.0B | 5 |
| Q3 FY2029 | $0.9B | $0.9B | $1.0B | 5 |
| Q2 FY2029 | $0.8B | $0.9B | $1.0B | 5 |
| Q1 FY2029 | $0.8B | $0.9B | $0.9B | 5 |
| Q4 FY2028 | $0.9B | $0.9B | $1.0B | 4 |
| Q3 FY2028 | $0.8B | $0.9B | $0.9B | 4 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 7, 2026 | +60.0% | $3.83 | $4.27 | +11.49% |
| ▲ Q1 FY2026 | Feb 24, 2026 | +33.3% | $2.77 | $2.56 | -7.58% |
| ▼ Q4 FY2025 | Nov 6, 2025 | -50.0% | $6.35 | $6.00 | -5.51% |
| ▼ Q3 FY2025 | Aug 7, 2025 | -211.1% | $9.41 | $9.69 | +2.98% |
| ▼ Q2 FY2025 | May 8, 2025 | -33.3% | $10.45 | $10.78 | +3.16% |
| ▼ Q1 FY2025 | Feb 20, 2025 | -105.3% | $10.52 | $10.71 | +1.81% |
| ▼ Q4 FY2024 | Nov 7, 2024 | -86.7% | $24.77 | $24.57 | -0.81% |
| ▲ Q3 FY2024 | Aug 8, 2024 | +42.9% | $20.43 | $20.87 | +2.15% |
Q2 FY2026+11.49%
Report Date
May 7, 2026
EPS Beat/Miss
+60.0%
Price Before
$3.83
Price After
$4.27
Q1 FY2026-7.58%
Report Date
Feb 24, 2026
EPS Beat/Miss
+33.3%
Price Before
$2.77
Price After
$2.56
Q4 FY2025-5.51%
Report Date
Nov 6, 2025
EPS Beat/Miss
-50.0%
Price Before
$6.35
Price After
$6.00
Q3 FY2025+2.98%
Report Date
Aug 7, 2025
EPS Beat/Miss
-211.1%
Price Before
$9.41
Price After
$9.69
Q2 FY2025+3.16%
Report Date
May 8, 2025
EPS Beat/Miss
-33.3%
Price Before
$10.45
Price After
$10.78
Q1 FY2025+1.81%
Report Date
Feb 20, 2025
EPS Beat/Miss
-105.3%
Price Before
$10.52
Price After
$10.71
Q4 FY2024-0.81%
Report Date
Nov 7, 2024
EPS Beat/Miss
-86.7%
Price Before
$24.77
Price After
$24.57
Q3 FY2024+2.15%
Report Date
Aug 8, 2024
EPS Beat/Miss
+42.9%
Price Before
$20.43
Price After
$20.87
Avg Beat Reaction+2.02%
Avg Miss Reaction+0.33%
Beat Rate3 / 8 quarters
Largest Move+11.49% (Q2 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: EVH ends December
Evolent Health, Inc. (EVH) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $-0.02 — beating the analyst consensus of $-0.05 by +60.0%. EVH has beaten EPS estimates for 2 consecutive quarters. The next EVH earnings date is expected around September 1, 2026.
Each quarter, investors track EVH earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. EVH revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
EVH's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
EVH earnings · 5 questionsEvolent Health, Inc.'s next earnings report is expected around September 1, 2026. EVH typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; EVH historically reports after market close (AMC).
EVH earnings datewhen is EVH earningsEVH next earnings datewhen does EVH report earningsEVH earnings calendar
▸ Source: FMP · Evolent Health, Inc. SEC filings · US GAAP · Evolent Health, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026